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A peptide corresponding to amino acid sequence 188-201 of the a-subunit of Torpedo AChR binds a-Bgtx. The S-S bridge 
between Cys 192 and 193 is essential for the binding as Tyr in position 189. The same sequence 188-201 corresponding 
to human AChR, which instead of Tyr has a Thr in position 189, binds a-Bgtx with a much lower efficiency. Monoclonal 
antibodies raised against Torpedo peptide 188-201 recognize Torpedo AChR and antibodies against Torpedo AChR re- 
cognize peptide 188-201 indicating that the synthetic peptide and the corresponding sequence in the native molecule share 
some immunological epitopes. With computer graphics and energy refinement a molecular model of this peptide has been 
elaborated. 
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1. INTRODUCTION 
The nicotinic acetylcholine receptor (AChR) is a 
neurotransmitter eceptor which, upon acetylcho- 
line binding, undergoes a conformational change 
which triggers ion permeability by opening a self- 
contained cation channel. AChR from vertebrate 
skeletal muscles and fish electric organs is a mem- 
brane complex of four protein subunits cy, &, y and 
6 of approx. 300 kDa [ 1,2]. In the functional recep- 
tor five subunits (LYZ, ,&, y, S) are arranged with 
pseudo-five-fold symmetry around the central- 
cation-conducting channel. Of the five subunits 
only the two a-subunits bind acetylcholine and the 
specific cholinergic antagonist a-bungarotoxin (W 
Bgtx) [ 11. Identification of the ACh binding site on 
the receptor a-subunits is a key point for under- 
standing the molecular mechanism underlying 
receptor activation. 
Chemical modification and affinity labeling 
studies of both native and detergent-solubilized 
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AChR indicate that a disulphide bridge is present 
on the a-subunit chains within 10 A of the 
acetylcholine binding site [3]. The two Cys 
building up this intrachain disulphide have been 
identified as residues 192 and 193 on the basis of 
affinity labeling studies [4]. Furthermore pro- 
teolytic fragments of the a-subunit containing 
residues 192-193 [5] and synthetic peptides cor- 
responding to the sequences 185-196 [6], 173-204 
[5] and 188-201 [7] bind cu-Bgtx. All these findings 
suggest that the sequence flanking residues 
192-193, which is one of the few sequences unique 
to a-subunit, is the major site responsible for the 
binding of a-Bgtx and cholinergic agents in the cy- 
subunit. 
For better understanding the molecular interac- 
tions regulating a-Bgtx binding to the m-subunit, 
we have: (i) synthesized a polypeptide segment cor- 
responding to the amino acid sequence 188-201 of 
the Torpedo and human a-subunits and smaller 
peptides of the Torpedo sequence flanking residues 
192-193 (188-194, 191-198 and 195-201) and 
tested their binding properties (in the presence and 
absence of chemical modifications of the amino 
acid side chains) towards cr-Bgtx; (ii) used 
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monoclonal antibodies against peptide 188-201 as 
tools for studying the conformation of peptide 
188-201 in solution and in the AChR molecule. 
The findings obtained and the available chemical 
and structural information have been employed 
for the development of a molecular model of this 
peptide by means of computer graphics and energy 
refinement. 
2. MATERIALS AND METHODS 
2.1. Peptides synthesis and immobilization 
Peptides (table 1) were synthetized manually or using a 
Beckman system 990 synthesizer by the stepwise solid-phase 
method proposed by Merrifield [8]. Final deprotection and 
cleavage of the peptides from the resin was performed by the 
low HF treatment proposed by Tern et al. 19). Peptide purifica- 
tion was achieved by gel filtration, ion-exchange and 
semipreparative r verse-phase liquid chromatography: the puri- 
ty was ascertained by RP-HPLC in different eluting systems 
and by amino acid analysis. Both the human and Torpedo 
188-201 sequence contained an additional Lys and the peptides 
overlapping the Torpedo 188-201 sequence an additional Gly at 
the NH2 terminus as spacer in order to improve the yield of im- 
mobilization. Peptides were immobilized on CNBr-activated 
Sepharose 4B (Pharmacia) in 0.1 M bicarbonate buffer, pH 8.3. 
The amount of coupled peptides (OS-l.Opmol of peptide/ml of 
Sepharose) was determined by amino acid analysis of the HCI 
hydrolysate. 
2.2. Chemical modification of peptide 188-201 bound to 
Sepharose 
2.2.1. Cys reduction and carboxymethylation 
Sepharose-peptide 188-201 conjugate, suspended in 0.1 M 
phosphate buffer, pH 8, was at first reduced by treatment with 
0.1 M DTT for 30 min at room temperature, then washed with 
deoxygenated and nitrogen saturated 0.1 M phosphate buffer, 
pH 6.0, until the washing was negative by Ellman’s test. Addi- 
tion, under nitrogen, of N-ethylmaleimide to a final concentra- 
tion of 0.1 M for 30 min gave a quantitative sulphydryl 
alkylation as judged by Ellman’s test. 
2.2.2. Tyr acylation 
Tyr acylation was achieved according to Smith [lo] treating 
1 ml of Sepharose-peptide 188-201 conjugate in 0.1 M 
Table 1 
Sequences of the synthetic peptides of the a-subunit of the 
Torpedo californica and human acetylcholine receptor, flank- 
ing residues 192-193 
Peptide crT 188-201 
Peptide (YT 188-194 
Peptide cuT 191-198 
Peptide (YT 195-201 
Peptide cuH 188-201 
KVYYTCCPDTPYLDI 
GVYYTCCP 
GTCCPDTPY 
GDTPYLDI 
KVTYSCCPDTPYLDI 
phosphate, pH 7.0, with 0.1 ml of a 10% acetic anhydride solu- 
tion in acetonitrile for 20 min. Then, excess reagent was re- 
moved by washing with buffers. Deacylation of the O-acetyl 
Tyr was achieved by treating the Sepharose-peptide O-acyl Tyr 
with 0.04 M hydroxylamine in 0.1 M phosphate, pH 7.0, for 30 
min according to Simpson et al. [ll]. 
2.2.3. &Carbonyl amidation 
Amidation was performed on the Sepharose-peptide con- 
jugate suspended in 0.01 M phosphate, pH 4.8, by adding a 
lOO-fold excess of both EDC and appropriate amine, buffered 
at the same pH, overnight: excess reactants were removed by ex- 
haustive washings. Incorporation of glycine methyl ester was 
complete as judged by amino acid analysis. 
2.3. Toxin purification and labeling 
cu-Bgtx was purified from the venom of Bungarus multicinc- 
tus according to Gotti et al. 1121 and was labeled with “‘1 by 
the chloramine T method [13] to a specific activity of 30 
pCi/nmol. 
2.4. Torpedo AChR purification 
AChR from Torpedo membranes was purified as described 
[14] using an affinity column with Naja naja siamensis toxin. 
Radiolabeling of AChR with lz51 was performed by the 
chloramine T method. 
2.5. cr-Bgtx binding to Sepharose-peptides 
2 nmol of various peptide-Sepharose conjugates were in- 
cubated with titrated amounts of iZSI+Bgtx in a final volume 
of lOOpI phosphate buffer saline (PBS) supplemented with 1% 
bovine serum albumin (BSA). Incubation was carried out both 
for 60 min and 24 h at room temperature after which samples 
were diluted with PBS and centrifuged in a microfuge for 3 min. 
The beads were washed again twice with PBS and then counted. 
2.6. Monoclonal and polyclonal antibody production and 
purification 
Monoclonal antibodies (mAbs) against Torpedo peptide 
188-201 were produced as described [15] using as immunogen 
peptide 188-201 conjugated to BSA. The conjugate contained 
approx. 40 molecules of peptide per molecule of BSA. 
Polyclonal antibodies (PAbs) against Torpedo AChR were ob- 
tained by immunization of rabbits with 1OOpg purified Torpedo 
AChR in complete Freund’s adjuvant. Two booster injections 
were administered two and four weeks later. PAbs were 
purified by ammonium sulfate precipitation and subsequent 
DEAE-cellulose ionic-exchange chromatography. 
2.7. Immunoprecipitation of “‘1-AChR by mAbs against 
peptide 188-201 
12*I-AChR from Torpedo electric organs was incubated with 
different concentrations of purified mAbs against peptide 
188-201 overnight at 4”C, followed by addition of carrier mAb 
and 50 gl of goat antimouse IgG. Precipitates were washed three 
times with PBS plus 0.1% Triton X-100 and counted in a y- 
counter. In a parallel experiment i2’I-AChR was incubated with 
cu-Bgtx for 60 min at 4°C and then with mAbs. 
2.8. Computer modeling 
The statistical predictive method of Chou and Fasman was 
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applied for establishing the probable secondary structure of the 
synthesized polypeptide [la]. All the molecular modeling steps 
were performed on an Evans and Sutherland PS300 graphics 
system using the program FRODO [17]. Part of the 
stereochemical refinement process was conducted at the model- 
ing stage applying the procedure of Hermans and McQueen [ 18) 
to subfragments of the polypeptide. Final minimizations and 
energy calculations were done using the program EREF [19]. 
Atomic coordinates for the C_(y positions of cu-Bgtx were those 
available from the Brookhaven Protein Data Bank file. 
3. RESULTS AND DISCUSSION 
3.1. Binding of ‘251-cz-Bgtx to peptides conjugated 
to Sepharose 
The peptide corresponding to Torpedo sequence 
188-201 had a maximal binding activity to cY-Bgtx. 
Shortening the peptide length on both sides of 
residues 192-193 largely decreased the binding 
capacity. The binding was also reduced when the 
S-S bridge between Cys 192 and 193 was reduced 
or alkylated. Restoring the disulphide bridge in 
mild oxidizing conditions e.g. potassium ferri- 
cyanide, restored the binding capacity (fig.1). 
In order to verify if other amino acids or side 
chain residues could be relevant for the toxin 
% 
binding to peptide 188-201, peptide 188-201- 
Sepharose conjugate was chemically modified 
in order to obtain 0-acyl Tyr peptide, and &car- 
boxylamide peptide. A decrease of the binding 
properties of the peptide was observed when the 
Tyr was 0-acylated, while @carboxy amidated 
peptide maintained the binding activity. Restoring 
the phenolic hydroxyl of Tyr by hydroxylamine, 
completely restored binding capacity (fig. 1). To 
further examine the relevance of Tyr for cu-Bgtx 
binding, we have synthetized the peptide corre- 
sponding to the sequence 188-201 of the cu-sub- 
unit of human AChR. This sequence differs 
from that of Torpedo by the substitution of Tyr 
189 with a Thr and of Thr 192 with a Ser. This pep- 
tide still specifically binds a-Bgtx but this binding 
is only 5-10070 of the binding of a-Bgtx to cor- 
responding peptide of the Torpedo sequence (fig. 
1). These findings indicate that Tyr in position 189 
is really relevant for a-Bgtx binding. These 
findings also suggest hat the sequence 188-201 is 
not the only site where cY-Bgtx binds, as it has been 
suggested by several authors [20], and/or that the 
simultaneous binding to other sites in the cr- 
subunit stabilizes or optimizes the binding to the 
n h c d 63 f * h .I 
PEPTI DES 
Fig. 1. Binding of ‘*‘I-cu-Bgtx to peptides corresponding to the amino acid sequence 188-201 of Torpedo and human a-subunit AChR 
and to chemically modified and shortened peptides of the 188-201 sequence of Torpedo AChR bound to Sepharose. (a) Peptide 
188-201 of Torpedo AChR in the oxidized form (expressed as 100%); (b) peptide 188-194; (c) peptide 191-198; (d) peptide 195-201; 
(e) peptide 188-201 reduced with DTT; (f) peptide 188-201 reduced and alkylated with N-ethylmaleimide; (g) peptide 188-201 with 
0-acylated Tyr; (h) peptide 188-201 with deacylated 0-acetyl Tyr; (i) peptide 188-201 with ,&carboxyl of aspartic acids and COOH 
terminal amidated; (j) peptide 188-201 of human AChR. 
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188-201 peptide. On the basis of these data and of Pro-Pro- segment within longer polypeptides or 
the amino acid sequence we studied the possible proteins, one of the two residues has a cis peptide 
molecular models of peptide 188-201. bond [23]. 
3.2. Peptide model 
Consideration of the secondary structure poten- 
tials for tetrapeptides in the 188-201 segment in- 
dicates a significant propensity for the &structure 
[ 161. On the other hand, the presence of an accessi- 
ble disulphide bridge linking two adjacent Cys, 
followed by a Pro, imposes structural constraints 
on the conformation attainable by the whole 
polypeptide. In particular, in order to attain pro- 
per S-S covalent bond formation, the peptide bond 
between adjacent Cys 192 and Cys 193 must adopt 
the unusual cis instead of the trans conformation 
[21, 221. Isomerization of the peptide bond may 
also occur at Pro residues, such as Pro 194. In this 
case, because of the five membered side chain ring 
constraint, the trans Pro structure is favoured by 
only 2 kcal/mol compared to the cis isomer. Under 
particular circumstances, such as occurrence of a - 
The 188-201 polypeptide was model built ac- 
cording to these criteria as extended structure, with 
chain reversal at Cys-192-Cys-193, and taking into 
consideration the two alternative structures for the 
Pro 194 peptide bond. Independent refinement of 
the two models indicated that lower overall energy 
can be attained by the structure displayed in fig.2, 
in which both 192-193 and 193-194 are cis peptide 
bonds. This structure could be refined to an overall 
energy of - 27 kcal/mol, while isomerization of 
Pro 194 (and subsequent rearrangement of the 
following residues) yielded a polypeptide confor- 
mation which could be refined to -14 kcal/mol. As 
can be seen from fig.2 the conformation proposed 
for the polypeptide is extended but not regular, 
especially at the turn where considerable contraints 
are present. Nevertheless the phi-psi backbone 
Fig.2. Two computer generated stereo pictures of the modeled 
188-201 peptide; the two views are approx. 90” apart. The S-S 
disulphide is in the upper part of the picture. Amino acid 
residues are labeled according to their sequence position. 
CPM 
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Fig.3. Immunoprecipitation of ‘251-Torpedo AChR by 
monoclonal antibodies raised in mouse against peptide 188-201 
bound to KLH. “‘I-Torpedo AChR was incubated, overnight 
at 4°C with the indicated concentrations of purified mAbs 
against peptide 188-201 (mT7, mT5, mT8) or control mAb 
(mT10). The complexes were then precipitated by addition of 50 
~1 of goat and antimouse IgG. Precipitates were washed twice 
and counted. 
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conformational parameters fall well within the ac- 
cepted limits of the Ramachandran plot [23]. 
Three hydrogen bonds connect the two antiparallel 
strands, but only Tyr-189-O-Thr-196-N shows 
adequate donor-acceptor orientation. 
The conformation proposed is consistent with a 
protein loop pointing to the receptor surface at the 
site of chain reversal. This is in accordance with 
solution studies showing the ready accessibility of 
the Cys-192-Cys-193 disulphide to reducing 
reagents [24]. The structure proposed here for the 
188-201 peptide of the a-subunit of the nicotinic 
acetylcholine receptor however does not allow one 
to extend the prediction to its binding mode to the 
surfaces of antagonists uch as snake neurotoxins, 
for which detailed molecular models are available 
[25]. Despite convincing evidence that the receptor 
peptide binds to the concave face of cy- 
neurotoxins, and that specific toxin residues have 
been identified as functionally important for the 
binding [26], we could model at least two peptide- 
neurotoxin complexes which equally well ac- 
counted for the existing data. 
3.3. Antibodies binding studies 
Concerning the question of the structure 
adopted by the free 188-201 peptide compared to 
that present in the native receptor, experiments 
with antibodies showed that PAbs raised in rabbits 
against Torpedo AChR and a mAbs (Mel Tl) 
raised against Torpedo AChR recognize, in an 
ELISA assay, peptide 188-201 (not shown). Fur- 
thermore three mAbs against peptide 188-201 are 
able to recognize Torpedo AChR (fig.3). However, 
these mAbs were unable to precipitate Torpedo 
AChR which had been preincubated with cY-Bgtx 
indicating that the antigenic site recognized by 
mAbs was hidden by cu-Bgtx (not shown). These 
data suggest hat the synthetic peptide 188-201 (i) 
can have, also in solution, a conformation similar 
to that shown in the native AChR since it is 
recognized by PAbs against AChR and mAbs 
against the peptide recognize AChR; (ii) is a rele- 
vant part of the binding site of a-Bgtx in the a- 
subunit since Abs against the synthetic peptide do 
not recognize AChR when it has bound cr-Bgtx. 
In conclusion, our results on the binding, struc- 
ture and immunological conformation of peptide 
188-201 indicate that this amino acid sequence is 
relevant for binding cholinergic agents also on the 
122 
native AChR and that this sequence cannot be 
altered without loss of toxin binding. 
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